CTHRC1: A New Candidate Biomarker for Improved Rheumatoid Arthritis Diagnosis

Askhat Myngbay, Yergali Bexeitov, Altynay Adilbayeva, Zhenisbek Assylbekov, Yevstratenko BP, Aitzhanova RM, Vyacheslav A. Adarichev, Bakhyt Matkarimov, Jeanette Kunz

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Background: The purpose of this study was to determine whether plasma levels of the collagen triple helix repeat containing 1 (CTHRC1) protein can serve as a blood-based biomarker for improved diagnosis of rheumatoid arthritis (RA) patients and monitoring of RA disease activity.

Methods: We measured levels of CTHRC1 in the plasma of patients diagnosed with RA, osteoarthritis (OA), reactive arthritis (ReA), as well as in healthy individuals. We then assessed the correlation between CTHRC1 protein and a range of indices including the 28-joint disease activity score (DAS28), rheumatoid factor (RF), C-reactive protein (CRP), anti-citrullinated protein antibodies (ACPA), erythrocyte sedimentation rate (ESR), as well as a panel of cytokines, including interleukin 1 beta (IL-1β), interleukin 6 (IL-6), interleukin 8 (IL-8), and interferon gamma (IFNγ). Receiver operating characteristic (ROC) analysis was further performed to assess the diagnostic value of CTHRC1.

Results: CTHRC1 plasma levels were significantly elevated in RA patients compared to healthy individuals, OA and ReA patients. ROC curve and risk score analysis suggested that plasma CTHRC1 can accurately discriminate patients with RA from healthy controls and may have practical value for RA diagnosis. CTHRC1 levels were positively associated with RF, ACPA, CRP, and disease activity based on the combined index of DAS28 with CRP (DAS28-CRP), and also strongly correlated with IL-1β, IL-6, IL-8, and IFNγ.

Conclusion: Our studies show that CTHRC1 is a sensitive and easy-to-measure plasma marker that differentiates between RA and healthy status and also distinguishes between RA and other forms of arthritis, such as OA and ReA. At the current level of understanding, plasma CTHRC1 levels may improve the diagnosis of RA and these findings warrant confirmation in a larger, more comprehensive patient population.

Original languageEnglish
Article number1353
Pages (from-to)1353
JournalFrontiers in Immunology
Volume10
Issue numberJUN
DOIs
Publication statusPublished - Jun 12 2019

Fingerprint

Rheumatoid Arthritis
Collagen
Biomarkers
Reactive Arthritis
Osteoarthritis
C-Reactive Protein
Rheumatoid Factor
Interleukin-8
Interleukin-1beta
ROC Curve
Interferon-gamma
Interleukin-6
Proteins
Antibodies
Joint Diseases
Blood Sedimentation
Physiologic Monitoring
Protein C
Arthritis
Cytokines

Keywords

  • Anti-citrullinated protein antibodies (ACPA)
  • Biomarker
  • Collagen triple helix repeat containing 1
  • CTHRC1
  • Disease activity score DAS28
  • Rheumatoid arthritis
  • Rheumatoid factor (RF)

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology

Cite this

CTHRC1: A New Candidate Biomarker for Improved Rheumatoid Arthritis Diagnosis. / Myngbay, Askhat; Bexeitov, Yergali; Adilbayeva, Altynay; Assylbekov, Zhenisbek; Yevstratenko BP; Aitzhanova RM; Vyacheslav A. Adarichev ; Matkarimov, Bakhyt; Kunz, Jeanette.

In: Frontiers in Immunology, Vol. 10, No. JUN, 1353, 12.06.2019, p. 1353.

Research output: Contribution to journalArticle

Myngbay, Askhat ; Bexeitov, Yergali ; Adilbayeva, Altynay ; Assylbekov, Zhenisbek ; Yevstratenko BP ; Aitzhanova RM ; Vyacheslav A. Adarichev ; Matkarimov, Bakhyt ; Kunz, Jeanette. / CTHRC1: A New Candidate Biomarker for Improved Rheumatoid Arthritis Diagnosis. In: Frontiers in Immunology. 2019 ; Vol. 10, No. JUN. pp. 1353.
@article{1a673cbe8ec241a0b6c6ace046e31c8c,
title = "CTHRC1: A New Candidate Biomarker for Improved Rheumatoid Arthritis Diagnosis",
abstract = "Background: The purpose of this study was to determine whether plasma levels of the collagen triple helix repeat containing 1 (CTHRC1) protein can serve as a blood-based biomarker for improved diagnosis of rheumatoid arthritis (RA) patients and monitoring of RA disease activity.Methods: We measured levels of CTHRC1 in the plasma of patients diagnosed with RA, osteoarthritis (OA), reactive arthritis (ReA), as well as in healthy individuals. We then assessed the correlation between CTHRC1 protein and a range of indices including the 28-joint disease activity score (DAS28), rheumatoid factor (RF), C-reactive protein (CRP), anti-citrullinated protein antibodies (ACPA), erythrocyte sedimentation rate (ESR), as well as a panel of cytokines, including interleukin 1 beta (IL-1β), interleukin 6 (IL-6), interleukin 8 (IL-8), and interferon gamma (IFNγ). Receiver operating characteristic (ROC) analysis was further performed to assess the diagnostic value of CTHRC1.Results: CTHRC1 plasma levels were significantly elevated in RA patients compared to healthy individuals, OA and ReA patients. ROC curve and risk score analysis suggested that plasma CTHRC1 can accurately discriminate patients with RA from healthy controls and may have practical value for RA diagnosis. CTHRC1 levels were positively associated with RF, ACPA, CRP, and disease activity based on the combined index of DAS28 with CRP (DAS28-CRP), and also strongly correlated with IL-1β, IL-6, IL-8, and IFNγ.Conclusion: Our studies show that CTHRC1 is a sensitive and easy-to-measure plasma marker that differentiates between RA and healthy status and also distinguishes between RA and other forms of arthritis, such as OA and ReA. At the current level of understanding, plasma CTHRC1 levels may improve the diagnosis of RA and these findings warrant confirmation in a larger, more comprehensive patient population.",
keywords = "Anti-citrullinated protein antibodies (ACPA), Biomarker, Collagen triple helix repeat containing 1, CTHRC1, Disease activity score DAS28, Rheumatoid arthritis, Rheumatoid factor (RF)",
author = "Askhat Myngbay and Yergali Bexeitov and Altynay Adilbayeva and Zhenisbek Assylbekov and {Yevstratenko BP} and {Aitzhanova RM} and {Vyacheslav A. Adarichev} and Bakhyt Matkarimov and Jeanette Kunz",
year = "2019",
month = "6",
day = "12",
doi = "10.3389/fimmu.2019.01353",
language = "English",
volume = "10",
pages = "1353",
journal = "Frontiers in Immunology",
issn = "1664-3224",
publisher = "Frontiers Media S. A.",
number = "JUN",

}

TY - JOUR

T1 - CTHRC1: A New Candidate Biomarker for Improved Rheumatoid Arthritis Diagnosis

AU - Myngbay, Askhat

AU - Bexeitov, Yergali

AU - Adilbayeva, Altynay

AU - Assylbekov, Zhenisbek

AU - Yevstratenko BP

AU - Aitzhanova RM

AU - Vyacheslav A. Adarichev

AU - Matkarimov, Bakhyt

AU - Kunz, Jeanette

PY - 2019/6/12

Y1 - 2019/6/12

N2 - Background: The purpose of this study was to determine whether plasma levels of the collagen triple helix repeat containing 1 (CTHRC1) protein can serve as a blood-based biomarker for improved diagnosis of rheumatoid arthritis (RA) patients and monitoring of RA disease activity.Methods: We measured levels of CTHRC1 in the plasma of patients diagnosed with RA, osteoarthritis (OA), reactive arthritis (ReA), as well as in healthy individuals. We then assessed the correlation between CTHRC1 protein and a range of indices including the 28-joint disease activity score (DAS28), rheumatoid factor (RF), C-reactive protein (CRP), anti-citrullinated protein antibodies (ACPA), erythrocyte sedimentation rate (ESR), as well as a panel of cytokines, including interleukin 1 beta (IL-1β), interleukin 6 (IL-6), interleukin 8 (IL-8), and interferon gamma (IFNγ). Receiver operating characteristic (ROC) analysis was further performed to assess the diagnostic value of CTHRC1.Results: CTHRC1 plasma levels were significantly elevated in RA patients compared to healthy individuals, OA and ReA patients. ROC curve and risk score analysis suggested that plasma CTHRC1 can accurately discriminate patients with RA from healthy controls and may have practical value for RA diagnosis. CTHRC1 levels were positively associated with RF, ACPA, CRP, and disease activity based on the combined index of DAS28 with CRP (DAS28-CRP), and also strongly correlated with IL-1β, IL-6, IL-8, and IFNγ.Conclusion: Our studies show that CTHRC1 is a sensitive and easy-to-measure plasma marker that differentiates between RA and healthy status and also distinguishes between RA and other forms of arthritis, such as OA and ReA. At the current level of understanding, plasma CTHRC1 levels may improve the diagnosis of RA and these findings warrant confirmation in a larger, more comprehensive patient population.

AB - Background: The purpose of this study was to determine whether plasma levels of the collagen triple helix repeat containing 1 (CTHRC1) protein can serve as a blood-based biomarker for improved diagnosis of rheumatoid arthritis (RA) patients and monitoring of RA disease activity.Methods: We measured levels of CTHRC1 in the plasma of patients diagnosed with RA, osteoarthritis (OA), reactive arthritis (ReA), as well as in healthy individuals. We then assessed the correlation between CTHRC1 protein and a range of indices including the 28-joint disease activity score (DAS28), rheumatoid factor (RF), C-reactive protein (CRP), anti-citrullinated protein antibodies (ACPA), erythrocyte sedimentation rate (ESR), as well as a panel of cytokines, including interleukin 1 beta (IL-1β), interleukin 6 (IL-6), interleukin 8 (IL-8), and interferon gamma (IFNγ). Receiver operating characteristic (ROC) analysis was further performed to assess the diagnostic value of CTHRC1.Results: CTHRC1 plasma levels were significantly elevated in RA patients compared to healthy individuals, OA and ReA patients. ROC curve and risk score analysis suggested that plasma CTHRC1 can accurately discriminate patients with RA from healthy controls and may have practical value for RA diagnosis. CTHRC1 levels were positively associated with RF, ACPA, CRP, and disease activity based on the combined index of DAS28 with CRP (DAS28-CRP), and also strongly correlated with IL-1β, IL-6, IL-8, and IFNγ.Conclusion: Our studies show that CTHRC1 is a sensitive and easy-to-measure plasma marker that differentiates between RA and healthy status and also distinguishes between RA and other forms of arthritis, such as OA and ReA. At the current level of understanding, plasma CTHRC1 levels may improve the diagnosis of RA and these findings warrant confirmation in a larger, more comprehensive patient population.

KW - Anti-citrullinated protein antibodies (ACPA)

KW - Biomarker

KW - Collagen triple helix repeat containing 1

KW - CTHRC1

KW - Disease activity score DAS28

KW - Rheumatoid arthritis

KW - Rheumatoid factor (RF)

UR - http://www.scopus.com/inward/record.url?scp=85068980041&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85068980041&partnerID=8YFLogxK

U2 - 10.3389/fimmu.2019.01353

DO - 10.3389/fimmu.2019.01353

M3 - Article

C2 - 31249576

AN - SCOPUS:85068980041

VL - 10

SP - 1353

JO - Frontiers in Immunology

JF - Frontiers in Immunology

SN - 1664-3224

IS - JUN

M1 - 1353

ER -